Home / Community / News / News

News

12/11/2014 - 9:31am

Isis Pharmaceuticals, Inc. has initiated a Phase I/II trial for ISIS-DMPKrx in patients affected by myotonic dystrophy type 1 (DM1).

12/09/2014 - 3:36pm

Dr. Tetsuo Ashizawa, MD, has focused his career on the search for DM treatments and care for those affected. His multi-disciplinary, patient-centric approach to care moves DM research out of the lab and into his clinic at the University of Florida.

10/16/2014 - 3:36pm

Dr. John Vissing and his colleagues at the University of Copenhagen recently tracked a group of 68 adults with myotonic dystrophy type 1 (DM1), measuring their endocrine function change over 8 years.

08/20/2014 - 11:05am

New research on the impact of the mother's age on congenitally affected offspring.

07/09/2014 - 3:49pm

Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals, Inc.) announced today that it has launched a Phase 1 clinical trial for IONIS-DMPKRX. IONIS-DMPKRX is designed to reduce the production of toxic dystrophia myotonic-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type 1 (DM1).

Partners

© Myotonic Dystrophy Foundation. All rights reserved.